Abaloparatide
FDA-approved drugAlso known as: Tymlos, 247062-33-5, BA058, BIM-44058, AVK0I6HY2U, abaloparatida, abaloparatidum, RefChem:58773
Abaloparatide (Tymlos, 247062-33-5, BA058) is classified under bone & mineral peptides, an FDA-approved drug.
Read the full guide: what the research shows on Abaloparatide →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
Abaloparatide is described in the provided sources as a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) used to manage/treat osteoporosis in postmenopausal women at high risk of fracture. (PMIDs: 36512663)
Mechanism (as reported)
Research described abaloparatide as a selective activator of the parathyroid hormone type 1 receptor. (PMIDs: 27533157)
Key findings (each cites a source)
- In a phase 3, double-blind randomized clinical trial (ACTIVE) in postmenopausal women with osteoporosis, new morphometric vertebral fractures occurred less frequently in the abaloparatide groups than in placebo over 18 months, and bone mineral density increases were greater with abaloparatide than placebo. (PMIDs: 27533157) [PMID 27533157]
- In the same ACTIVE trial, the Kaplan-Meier estimated event rate for nonvertebral fracture was lower with abaloparatide than placebo. (PMIDs: 27533157) [PMID 27533157]
- In ACTIVE, incidence of hypercalcemia was lower with abaloparatide (3.4%) than with teriparatide (6.4%). (PMIDs: 27533157) [PMID 27533157]
- A living systematic review and network meta-analysis reported that abaloparatide (and teriparatide) reduced clinical and radiographic vertebral fractures, while increasing withdrawals due to adverse events (WAEs). (PMIDs: 36592455) [PMID 36592455]
- The living systematic review and network meta-analysis reported that abaloparatide, teriparatide, and sequential romosozumab, then alendronate, may be more effective than bisphosphonates in reducing clinical fractures for 17 to 24 months in older postmenopausal females at very high fracture risk. (PMIDs: 36592455) [PMID 36592455]
- The provided sources describe abaloparatide as a synthetic peptide analog of PTHrP used to manage/treat osteoporosis, and note that FDA approval is for postmenopausal women at high risk of fracture due to osteoporosis. (PMIDs: 36512663) [PMID 36512663]
- An overview article described that teriparatide and abaloparatide target the parathyroid hormone-1 receptor and are given by daily subcutaneous injection for up to 2 years (as described in the source). (PMIDs: 35279261) [PMID 35279261]
- Clinical guidance documents in the provided sources state that multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk, with acceptable risk-benefit and safety profiles (general statement about pharmacologic options). (PMIDs: 30907953) [PMID 30907953]
Independent test grades
No independent third-party test data is available for Abaloparatide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (14)
Consolidated from PubMed — each links to the original record.
- Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment.
Lee KI, Chen JH, Chen KH · International journal of molecular sciences · 2026 · PMID 41596293
- Abaloparatide.
Akel M, Patel P, Parmar M · 2026 · PMID 36512663
- Recent Advances in Osteoporosis Therapeutics.
Sølling AS, Langdahl BL, Cosman F · Annual review of medicine · 2026 · PMID 41252575
- Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.
Tabatabai L, Cosman F, Curtis JR, DeSapri KT, LaBaume CT, Reginster JY · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025 · PMID 39551187
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Ebina K, Etani Y, Noguchi T, Nakata K, Okada S · Journal of bone and mineral metabolism · 2025 · PMID 39009890
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C · Annals of internal medicine · 2023 · PMID 36592455
- Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
FAQ
- What is Abaloparatide?
- Abaloparatide (Tymlos, 247062-33-5, BA058) is classified under bone & mineral peptides, an FDA-approved drug. Research goals associated with it include bone & mineral density.
- Is Abaloparatide FDA-approved?
- Yes — Abaloparatide is approved by the FDA (marketed as Tymlos, 247062-33-5).
- What does the research on Abaloparatide say?
- peptideone aggregates 14 references from PubMed for Abaloparatide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.